How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

808 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. First in human study with a prodrug of galantamine: Improved benefit-risk ratio? Full Text available with Trip Pro

First in human study with a prodrug of galantamine: Improved benefit-risk ratio? Gln-1062 (Memogain) is a pharmacologically inactive prodrug of galantamine. Owing to its lipophilic nature, it preferentially enters the brain, where it is cleaved into active galantamine. Gln-1062 is expected to have fewer peripheral side effects than other cholinesterase inhibitors, with improved effectiveness.This was a double-blind, comparator and placebo-controlled, sequential cohort, single ascending dose (...) study in 58 healthy subjects with Gln-1062 in doses of 5.5, 11, 22, 33, and 44 mg, compared with oral galantamine 16 mg and donepezil 10 mg. Safety, tolerability, pharmacokinetics, and pharmacodynamics were assessed.Gln-1062 doses up to 33 mg were well tolerated and induced a dose-dependent increase in the plasma concentrations of Gln-1062 and galantamine. Gln-1062 had a dose-dependent positive effect on verbal memory and attention, mainly in the first hours after drug administration.Gln-1062

2016 Alzheimer's & dementia : translational research & clinical interventions Controlled trial quality: uncertain

42. Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine Full Text available with Trip Pro

Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) project designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia, identified three drug mechanisms of particular interest: dopaminergic, cholinergic, and glutamatergic. Galantamine is an acetylcholinesterase inhibitor and a positive (...) allosteric modulator of the α7 nicotinic receptors. Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist. There is evidence to suggest that the combination of galantamine and memantine may be effective in the treatment of cognitive impairments in schizophrenia. There is a growing body of evidence that excess kynurenic acid (KYNA) is associated with cognitive impairments in schizophrenia. The α-7 nicotinic and the NMDA receptors may counteract the effects of kynurenic acid (KYNA) resulting

2016 Schizophrenia Research: Cognition

43. Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil Full Text available with Trip Pro

Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil This study compares the efficacy of the cholinesterase inhibitor (ChEI) galantamine on cognition in patients with mild-to-moderate Alzheimer's dementia (AD) who were either naïve to ChEI drugs or who had failed a trial of the ChEI donepezil.Outpatients with AD were sequentially referred for screening and enrollment. Current outpatients who had taken donepezil for at least 6 months (...) without demonstrated efficacy on cognition were switched to galantamine (switched group). New outpatients with no ChEI prescription history were classified as the naïve group and were given galantamine. The primary outcome measures for the between-group comparison were response rate on cognition at 26 and 52 weeks (categorical) and change on the Korean version of the Alzheimer's Disease Assessment Scale-cognitive subscale (dimensional). Secondary cognitive outcomes were measured using the subset

2016 Psychiatry investigation

44. In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer’s Disease Full Text available with Trip Pro

In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer’s Disease Alzheimer's disease (AD) is a chronic pathological condition that leads to neurodegeneration, loss of intellectual abilities, including cognition and memory, and ultimately to death. It is widely recognized that AD is a multifactorial disease, where different pathological cascades (mainly amyloid and tau) contribute to neural death and to the clinical outcome related

2016 Scientific reports

45. Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury. Full Text available with Trip Pro

Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury. We report findings from a 12-week randomized double-blinded placebo-controlled trial of methylphenidate or galantamine to treat emotional and cognitive complaints in individuals (n=32) with a history of PTSD, TBI, or both conditions. In this small pilot study, methylphenidate treatment was associated with clinically meaningful

2015 Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology Controlled trial quality: predicted high

46. Galantamine attenuates amyloid-β deposition and astrocyte activation in APP/PS1 transgenic mice. (Abstract)

Galantamine attenuates amyloid-β deposition and astrocyte activation in APP/PS1 transgenic mice. While galantamine may not provide a cure for Alzheimer's disease (AD), it decelerates the progression and provides symptomatic relief for this disorder. The aim of this study was to investigate the effect of chronic galantamine treatment on cognitive performance, Aβ deposition and astrocyte activation in the transgenic APP/PS1 mouse model of AD. Galantamine (5mg/kg, i.p.) or 0.9% saline (...) was administrated twice daily for eight weeks in 10-month-old APP/PS1 mice. In addition a separate group of 10-month old male C57BL/6 wild type mice was included as a reference control. Compared with saline treated APP/PS1 mice, galantamine treated mice exhibited significantly improved escape latencies on Days 6 and 7 of testing (p<0.05) and significantly decreased numbers of platform crossings (p<0.01) as assessed in the Morris water maze. Galantamine reduced the total area of amyloid load within

2015 Experimental Gerontology

47. Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine (GalaNic) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02420327 Recruitment Status : Completed First Posted : April 17, 2015 Results First Posted : August 17, 2018 Last Update Posted : August

2015 Clinical Trials

48. Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer’s disease Full Text available with Trip Pro

Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer’s disease Galantamine hydrobromide (GH) is an effective drug for Alzheimer's disease. It is currently delivered via the oral route, and this might cause nausea, vomiting, and gastrointestinal disturbance. In the present work, GH was formulated in a gel-type drug reservoir and then optimized by using response surface methodology (RSM) based on central composite design

2015 International journal of nanomedicine

49. Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine Full Text available with Trip Pro

Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine Glutamate receptors sensitive to N-methyl-D-aspartate (NMDA) are involved in embryonic brain development but their activity may be modulated by the kynurenine pathway of tryptophan metabolism which includes an agonist (quinolinic acid) and an antagonist (kynurenic acid) at these receptors. Our previous work has shown that prenatal inhibition of the pathway produces (...) potentiation was decreased in the kynurenine-treated rats and in the KMO(-/-) mice, but galantamine reversed this effect in the presence of nicotinic receptor antagonists, consistent with evidence that it can potentiate glutamate at NMDA receptors. It is concluded that interference with the kynurenine pathway in utero can have lasting effects on brain function of the offspring, implying that the kynurenine pathway is involved in the regulation of early brain development.Copyright © 2015 The Authors

2015 Neuroscience

50. Galantamine protects against lipopolysaccharide-induced acute lung injury in rats Full Text available with Trip Pro

Galantamine protects against lipopolysaccharide-induced acute lung injury in rats Lipopolysaccharide (LPS)-induced endotoxemia triggers the secretion of proinflammatory cytokines and can cause acute lung injury (ALI). The high mobility group box 1 (HMGB1) protein plays an important role as a late mediator of sepsis and ALI. Galantamine (GAL) is a central acetylcholinesterase inhibitor that inhibits the expression of HMGB1. This study evaluated the effects of GAL by measuring levels

2015 Brazilian Journal of Medical and Biological Research

51. Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial. (Abstract)

Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial. 25109421 2015 04 22 2018 12 02 1545-7214 22 9 2014 Sep The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry Am J Geriatr Psychiatry Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial. 951 10.1016/j.jagp.2014.04.010 S1064 (...) -7481(14)00166-3 Bogaisky Michael M Division of Geriatrics, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY. eng Letter Comment 2014 06 02 England Am J Geriatr Psychiatry 9309609 1064-7481 0 Antipsychotic Agents 0 Cholinesterase Inhibitors 0D3Q044KCA Galantamine L6UH7ZF8HC Risperidone IM Am J Geriatr Psychiatry. 2014 Apr;22(4):341-8 24035407 Am J Geriatr Psychiatry. 2014 Sep;22(9):951 25109420 Antipsychotic Agents therapeutic use Cholinesterase Inhibitors therapeutic use

2015 The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry Controlled trial quality: uncertain

52. Galantamine for dementia in people with Down syndrome. (Abstract)

Galantamine for dementia in people with Down syndrome. Alzheimer's dementia (AD) is the most common form of dementia in people with Down Syndrome (DS). Acetylcholine is a chemical found in the brain that has an important role in memory, attention, reason and language. Galantamine both inhibits the activity of acetylcholinesterase and increases the level of acetylcholine. Galantamine can improve cognitive function and slow the decline of AD in the general population over time. It is important (...) to note that people with DS tend to present with AD at a much younger age than the normal population as well as having subtle differences in physiology (e.g. metabolism and heart rate) and may therefore have different requirements from the general population.To determine the effectiveness and safety of galantamine for people with DS who develop AD.CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, BIOSIS, SCI, SSCI and the NRR were searched up to October 2008. We contacted the manufacturers of galantamine

2009 Cochrane

53. Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea Full Text available with Trip Pro

Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea Suh GH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to determine the cost-effectiveness of including galantamine in the treatment of mild-to-moderately severe Alzheimer’s disease, compared with usual care. The authors concluded that usual care plus galantamine was cost-effective compared with usual care alone. The methods were appropriate and both the methods and results were reported adequately

2009 NHS Economic Evaluation Database.

54. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine

Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

55. Pharmacological investigations of new galantamine peptide esters Full Text available with Trip Pro

Pharmacological investigations of new galantamine peptide esters Galantamine hydrobromide (GAL) is a reversible acetylcholinesterase inhibitor, with properties to increase the concentration of acetylcholine in several brain structures. The aim of this study is to determine the effect of new galantamine peptide esters: 3,4-dichlorophenyl-alanil-leucil-glycine-galantamine (GAL-LEU) and 3,4-dichlorophenyl-alanil-valil-glycine-galantamine (GAL-VAL), on locomotor activity in mice and cognitive

2014 Biotechnology, biotechnological equipment

56. Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis. (Abstract)

Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis. The role of currently available drugs for Alzheimer's disease (AD) has been controversial, with some national formularies restricting their use, and health economists questioning whether the small clinical effects are economically worthwhile.To estimate the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine (...) for the treatment of AD.Double-blind, placebo-controlled, with random assignment to a cholinesterase inhibitor or memantine trials were included into the pooled studies.Cognitive effects were significant for all drugs, ranging from a -1.29 points mean difference (95% CI -2.30 to -0.28) in the 20 mg daily memantine trials to -3.20 points (95% CI -3.28 to -3.12) in the 32 mg daily galantamine group. Only memantine had no effect on the Clinicians' Global Impression of Change scale. No behavioral benefits were

2014 Journal of Alzheimer's disease : JAD

57. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. Full Text available with Trip Pro

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. Currently available treatments for Alzheimer's disease (AD) can produce mild improvements in cognitive function, behavior, and activities of daily living in patients, but their influence on long-term survival is not well established. This study was designed to assess patient survival and drug efficacy following a 2-year galantamine treatment in patients with mild to moderately severe AD.In (...) this multicenter, double-blind study, patients were randomized 1:1 to receive galantamine or placebo. One primary end point was safety; mortality was assessed. An independent Data Safety Monitoring Board monitored mortality for the total deaths reaching prespecified numbers, using a time-to-event method and a Cox-regression model. The primary efficacy end point was cognitive change from baseline to month 24, as measured by the Mini-Mental State Examination (MMSE) score, analyzed using intent-to-treat analysis

2014 Neuropsychiatric disease and treatment Controlled trial quality: predicted high

58. Galantamine versus Risperidone for Agitation in People with Dementia: A Randomized, Twelve-Week, Single-Center Study. (Abstract)

Galantamine versus Risperidone for Agitation in People with Dementia: A Randomized, Twelve-Week, Single-Center Study. To examine the effects of galantamine and risperidone on agitation in patients with dementia.A total of 100 patients with dementia and neuropsychiatric symptoms (mean age ± SD: 78.6 ± 7.5 years; 67% female) were included in this 12-week, randomized, parallel-group, controlled, single-center trial. The participants received galantamine (n = 50; target dose: 24 mg) or risperidone (...) (n = 50; target dose: 1.5 mg) for 12 weeks.Both galantamine and risperidone treatment resulted in reduced agitation. However, risperidone showed a significant advantage over galantamine both at week 3 (mean difference in total Cohen-Mansfield Agitation Inventory score: 3.7 points; p = 0.03) and at week 12 (4.3 points; p = 0.01).Agitation improved in both groups, even if the treatment effects were more pronounced in the risperidone group; however, the effects on cognition and other aspects

2014 Dementia and Geriatric Cognitive Disorders Controlled trial quality: uncertain

59. The prediction of response to Galantamine treatment in Patients with mild to moderate Alzheimer's Disease. Full Text available with Trip Pro

The prediction of response to Galantamine treatment in Patients with mild to moderate Alzheimer's Disease. The prediction of efficacy in long-term treatment of acetylcholinesterase inhibitors (AChEIs) is a major clinical issue, although no consistently strong predictive factors have emerged thus far. The present analyses aimed to identify factors for predicting long-term outcome of galantamine treatment. Analyses were conducted with data from a 24 weeks randomized, double-blind, placebo (...) controlled trial to evaluate the efficacy and the safety of galantamine in the treatment of 303 patients with mild to moderate AD. Patients were divided into responders (4 or more point improvement of ADAScog scores at 24 weeks of treatment) and non-responders. We explored whether patients' background (e.g. sex, age, and duration of disease) and scores of cognitive scales at early stage, are relevant to the long-term response to AChEIs. Predictive values were estimated by the logistic regression model

2014 Current Alzheimer research Controlled trial quality: uncertain

60. Galantamine and Memantine for Cognitive Impairments in Schizophrenia

Galantamine and Memantine for Cognitive Impairments in Schizophrenia Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02234752 Recruitment Status : Terminated (Funding no longer available and PI no longer working at the institution) First Posted : September 9, 2014 Results First Posted

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>